Quantum BioPharma Advances LUCID-MS Therapy for Multiple Sclerosis with Positive Phase 1 Results

Multiple sclerosis (MS) remains one of the most challenging neurological diseases due to its progressive nature, unpredictable course, and lack of a cure. Affecting more than 2.8 million people worldwide and approximately 1 million in the USA, many patients continue to experience worsening disability despite available immune-modulating therapies. Current treatments often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression.

Against this backdrop, Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing Lucid-MS, a patented therapeutic candidate designed to target demyelination and provide neuroprotection in MS to address loss of mobility and function. The company recently announced the completion of Phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated. This milestone is critical for advancing into later-stage trials.

In April 2026, Quantum BioPharma reached a significant milestone by submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for LUCID-MS. The submission marks a key step toward initiating Phase 2 studies, where the therapy's efficacy will be evaluated in MS patients. The LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity, which affects the loss of mobility or control of a person's body.

MS is a chronic autoimmune and neurodegenerative disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin deteriorates, communication between nerves becomes disrupted, leading to symptoms that can include vision problems, muscle weakness, and coordination difficulties. Current disease-modifying therapies primarily target the inflammatory component of MS, but there remains a significant gap in treatments that promote remyelination or neuroprotection. LUCID-MS aims to fill this gap by focusing on myelin repair and protection, potentially slowing or halting disease progression.

The positive Phase 1 safety data and the IND submission position Quantum BioPharma to potentially address a major unmet medical need. If successful in later trials, LUCID-MS could become a foundational therapy for MS patients, complementing existing anti-inflammatory treatments. The implications of this announcement are significant for the MS community, as a therapy that directly protects or restores myelin could change the treatment paradigm and improve outcomes for millions of patients worldwide.

For further information, the company's newsroom provides updates at https://ibn.fm/QNTM. Forward-looking statements in this article involve risks and uncertainties; full disclaimers are available at http://IBN.fm/Disclaimer.